Surface Oncology will contribute anti-CD39 SRF617 and Merck anti-PD-1 Keytruda in the phase 1/1b trial involving patients with solid tumors.
Seneca Biopharma is working with the FDA to finalize the design of a phase 3 trial of neural stem cell NSI-566 for the treatment of ALS.
Adaptimmune iT SPEAR T cells, which target antigens associated with solid tumors, can be derived from stem cells and kill cancer in vitro.
Massachusetts-based Vertex Pharmaceuticals (NASDAQ: VRTX) and Swiss Crisper Therapeutics (NASDAQ: CRSP) have announced the designation…
Gilead JAK1 inhibitor Filgotinib 200 mg was shown to more effectively induce and maintain ulcerative colitis remission than a placebo.
Vaxart chose a lead oral COVID-19 vaccine candidate based on pre-clinical animal models and partnered with KindredBio for manufacturing.
Inovio COVID-19 vaccine INO-4800 induced robust neutralizing antibody and T cell immune responses in animal models, Nature publication shows.
BioCryst Pharmaceuticals (NASDAQ:BCRX) has iniated a phase 1 trial of the anti-viral Galidesivir in Brazil with funding from the NIAID.
Altimmune will develop the vaccine, AdCOVID, with University of Alabama at Birmingham, UAB, scientists to prepare for Phase 1 trials in Q3.